Top View
- Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism
- Pharmacological Drugs Inducing Ototoxicity, Vestibular Symptoms and Tinnitus: a Reasoned and Updated Guide
- What Is Necessary and Sufficient to Provide Naltrexone Or Buprenorphine in Primary Care Settings?
- Clinical Policy: Morphine Sulfate/Naltrexone Extended- Release (Embeda)
- Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
- Medication: Naltrexone 1 Mg
- Opioid Antagonist (Naltrexone) Modulation of Cerebellar Development: Histological and Morphometric Studies
- Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, Or Naltrexone Maintenance Therapy
- Naltrexone-Buprenorphine Interactions: Effects on Cocaine Self-Administration Nancy K
- Efficacy Naltrexone Treatment Alcohol Dependence
- Opioid Treatment Programs and Related Federal Regulations
- Continuing Buprenorphine Or Naltrexone-Containing Drugs in Peri-Operative Patients
- Antagonists in the Medical Management of Opioid Use Disorders: Historical and Existing Treatment Strategies
- Low Dose Naltrexone Patient Information Sheet
- Vivitrol (Naltrexone for Extended-Release Injectable Suspension) Policy Number: C5775-A
- Your Pharmacist / Your Advocate
- Drug-Induced Endocrinopathies and Diabetes
- Prescribing Information
- Trial of Naltrexone & Dextromethorphan for Gulf War
- Trends in the Use of Methadone, Buprenorphine, and Extended
- (WFSBP) Guidelines for the Biological Treatment of Paraphilias
- Maintenance Pharmacologic Therapies for Opioid Use Disorders: Beyond Opioid Agonists
- Morphine and Naltrexone | Memorial Sloan Kettering Cancer Center
- Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women
- EMBEDA® (Morphine Sulfate and Naltrexone Hydrochloride) Extended-Release Capsules
- Opioid System Is Necessary but Not Sufficient for Antidepressive Actions of Ketamine in Rodents
- Ketamine/Esketamine: Putative Mechanisms of Action
- EMBEDA (Morphine Sulfate and Naltrexone Hydrochloride)
- Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans
- Molecular Mechanisms by Which Salvinorin a Binds to and Activates the Kappa-Opioid Receptor
- National Practice Guideline
- Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: a Brief Guide
- Partial Kappa Opioid Agonist Activity?
- Naltrexone Fact Sheet
- An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People with Opioid Dependence
- Salvinorin A, a Kappa-Opioid Receptor Agonist Hallucinogen: Pharmacology and Potential Template for Novel Pharmacotherapeutic Agents in Neuropsychiatric Disorders
- EMBEDA (Morphine Sulfate and Naltrexone Hydrochloride) RATIONALE for INCLUSION in PA PROGRAM
- Nalmefene and Alcohol Dependence: a New Approach Or the Same Old Unacceptable Marketing?
- List of Restricted and Controlled Drugs Cd(A) [ 2007-2008 ]
- MEDICATION GUIDE VIVITROL® (Viv-I-Trol) (Naltrexone for Extended-Release Injectable Suspension)
- Opioid A4: Antidotes in Depth
- Pharmacokinetics and Pharmacodynamics of Salvinorin a and Salvia Divinorum: Clinical and Forensic Aspects
- Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes
- Clinically Available NMDA Receptor Antagonist Dextromethorphan Attenuates Acute Morphine Withdrawal in the Neonatal Rat
- Low Dose Naltrexone and Ketamine for COVID Treatment - a Clinical Trial
- Buprenorphine and Naltrexone Fact Sheet
- Effects of Naltrexone and Nalmefene on Subjective Response to Alcohol Among Non-Treatment-Seeking Alcoholics and Social Drinkers
- Naloxone for Opioid Overdose
- Naltrexone and Alcoholism Treatment 28: Treatment Improvement Protocol (TIP) Series 28
- XR-Naltrexone: a Step-By-Step Guide Step 1: Step 2: Step 3: Patient History Medical Evaluation Shared Decision-Making
- Low-Dose Naltrexone for Treatment of Psychiatric Disorders
- Intramuscular Naltrexone Targeting Adherence in Alcohol Dependency Treatment